IP Library Granted Patent US 10,513,540
Granted Patent B2
US 10,513,540 · App. 14/418,726 · Granted Dec 24, 2019

Modulation of the immune response

Inventors: Richard S. Blumberg (Waltham, MA); Vijay K. Kuchroo (Newton, MA); Yu-Hwa Huang (Boston, MA); Chen Zhu (Brookline, MA); Ana C. Anderson (Brookline, MA)
Assignee: The Brigham and Women's Hospital, Inc.
C07K7/08A61K38/10A61K39/3955C07K14/70503C07K16/2803C07K16/30A61K2039/505A61K2039/507C07K2317/31C07K2317/73C07K2319/30Y02A50/463Y02A50/466
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,513,540
App. No.
14/418,726
Granted
Dec 24, 2019
Kind
B2
Abstract

Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.

Claims (12)

1. A composition comprising a proteo-mimetic agent comprising SEQ ID NO: 31.

2. The composition of claim 1 , wherein the proteo-mimetic agent is fused to a heterologous polypeptide, or portion thereof.

3. The composition of claim 2 , wherein the heterologous polypeptide is selected from the group consisting of transferrin, serum albumin, or an immunoglobulin heavy chain constant region (Fc).

4. The composition of claim 1 , wherein the proteo-mimetic agent is conjugated to a polymer.

5. The composition of claim 4 , wherein the polymer is polyethylene glycol (PEG).

6. A composition comprising a fusion polypeptide comprising

(a) a proteo-mimetic agent consisting of SEQ ID NO: 30; and

(b) a heterologous polypeptide, or portion thereof.

7. The composition of claim 6 , wherein the heterologous polypeptide is selected from the group consisting of transferrin, serum albumin, or an immunoglobulin heavy chain constant region (Fc).

8. A composition comprising a conjugate molecule comprising

(a) a proteo-mimetic agent consisting of SEQ ID NO: 30; and

(b) a polymer, wherein the polymer is polyethylene glycol (PEG).

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 10, 2018
From: BRIGHAM AND WOMEN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048991/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2015
From: BLUMBERG, RICHARD S.; KUCHROO, VIJAY K.; HUANG, YU-HWA; ZHU, CHEN; ANDERSON, ANA C.
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 035498/0471 →
Continuity (2)
Provisional Application 61677596 · Jul 31, 2012
Related Publication 20150225457A1 · Aug 13, 2015